Lung cancer remains a leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancer cases. Squamous NSCLC, a distinct histologic subtype accounting for up to one-third of all NSCLC cases, is challenging to treat due to its presentation, patient characteristics, and tumor location. In this activity, Drs. Ramaswamy Govindan and Paul K. Paik discuss the importance of the clinicopathological classification and molecular testing, including recent changes in guideline-directed testing recommendations, for metastatic squamous NSCLC. Their discussions, which also address case study-based clinical scenarios, delve into clinical advances in therapeutic management of this challenging malignancy, and provide practical insights into optimal therapeutic choice and management of adverse reactions. Join Drs. Govindan and Paik on this lively discussion for a critical practice-focused update on the management of metastatic squamous NSCLC.
2.00 AMA PRA Category 1 CreditsTM
2.00 ANCC Contact Hours
0.75 Pharmacology Hours
This activity is intended for a national audience of oncologists, nurse practitioners, nurses, physician assistants, and other clinicians.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Ramaswamy Govindan, MD
Professor of Medicine
Division of Medical Oncology
Washington University School of Medicine
St. Louis, Missouri
Paul K. Paik, MD
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York